Last $2.03 USD
Change Today +0.02 / 1.00%
Volume 101.2K
SNGX On Other Exchanges
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $2.50
52 Week Low
10/14/14 - $1.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a clinical stage biopharmaceutical company, is engaged in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and various biodefense vaccines and therapeutics. The company operates in, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease, acute radiation enteritis, and chronic graft-versus-host disease, as well as novel innate defense regulator technology for the treatment of oral mucositis. The Vaccines/BioDefense segment offers RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; OrbeShield, a gastrointestinal acute radiation syndrome program; and SGX943, a melioidosis therapeutic. These vaccine programs are supported by the company’s heat stabilization technology, known as ThermoVax. The company has collaboration with Intrexon Corporation to focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

17 Employees
Last Reported Date: 09/30/14
Founded in 1987

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Execdutive Officer and Presid...
Total Annual Compensation: $641.0K
Acting Chief Financial Officer, Vice Presiden...
Total Annual Compensation: $276.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $244.0K
Compensation as of Fiscal Year 2013.

soligenix inc (SNGX) Key Developments

Soligenix, Inc. Appoints Rasappa Arumugham as Vice President of Biopharmaceutical Development

Soligenix, Inc. announced that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar(R), Tetramune(TM), HibTITER(R), Meningitec(R) Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines. Most recently, Dr. Arumugham served as the Head of Microbial Vaccines Analytics at Merck's Manufacturing Division.

Soligenix, Inc. Wins Contract of $24.7 Million for Development of Thermostabilization Technology

Soligenix, Inc. announced that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). The objectives of the contract are to advance the development of company's thermostabilization technology, ThermoVax(TM), combined with the company's ricin toxin vaccine, Rivax(TM), as a medical countermeasure (MCM) to prevent the effects of ricin exposure. The contract contains a 16 month base period providing financial support of approximately $5.8 million, followed by several contract options that would extend the contract award for up to six years. If all contract options are exercised, the total award will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax(TM) with the US Food and Drug Administration (FDA).

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

Soligenix, Inc. announced that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). SGX301 is a novel, first-in-class, photodynamic therapy utilizing safe visible light for activation. The active ingredient, synthetic hypericin, is a potent photosensitizer which is topically applied to skin lesions and activated by visible fluorescent light. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging chemotherapeutic drugs and other photodynamic therapies that are dependent on ultraviolet A (UVA) exposure. Topical hypericin has demonstrated safety in a Phase 1 clinical study in healthy volunteers. In a Phase 2, double-blind, placebo-controlled clinical study in CTCL patients, the drug was safe and well tolerated, with 58.3% of the CTCL patients responding to SGX301 treatment compared to only 8.3% receiving placebo (p < 0.04). Based on the positive results demonstrated in the Phase 2 study of SGX301, the upcoming Phase 3 protocol will be a highly powered, double-blind, randomized, placebo-controlled, multicenter trial and will seek to enroll approximately 120 patients. The trial will consist of three treatment cycles, each of 8 weeks duration. Treatments will be administered twice weekly for the first 6 weeks and treatment response will be determined at the end of Week 8. In the first treatment cycle, approximately 80 patients will receive SGX301 and 40 will receive placebo treatment of their index lesions. In the second cycle, all patients will receive SGX301 treatment of their index lesions and in the third (open-label) cycle all patients will receive SGX301 treatment of all their lesions. Subjects will be followed for an additional 6 months after the completion of treatment. The primary clinical efficacy endpoint is treatment response assessed using the CAILS (Composite Assessment of Index Lesion Severity) score evaluating the three worst index lesions at the end of Cycle 1 (Week 8). The trial is anticipated to begin in the first half of 2015 with primary data available in the second half of 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $2.03 USD +0.02

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at